Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of “Buy” from Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI) has been given an average recommendation of “Buy” by the eight research firms that are covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $41.22.

DNLI has been the subject of several research analyst reports. UBS Group decreased their price target on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 9th. HC Wainwright decreased their target price on Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating for the company in a research note on Wednesday, February 28th. The Goldman Sachs Group lowered their price target on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, February 29th. Finally, Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Denali Therapeutics in a report on Wednesday, February 28th.

Denali Therapeutics Trading Up 2.0 %

Shares of DNLI opened at $17.14 on Friday. The stock has a market cap of $2.44 billion, a P/E ratio of -15.87 and a beta of 1.39. The stock’s 50-day moving average price is $18.95 and its two-hundred day moving average price is $18.86. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.31.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.05). Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same quarter in the prior year, the business posted ($0.75) EPS. As a group, equities analysts forecast that Denali Therapeutics will post -2.61 EPS for the current year.

Insider Transactions at Denali Therapeutics

In related news, insider Carole Ho sold 2,784 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $17.29, for a total value of $48,135.36. Following the sale, the insider now owns 145,010 shares of the company’s stock, valued at approximately $2,507,222.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Carole Ho sold 2,784 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $48,135.36. Following the completion of the transaction, the insider now owns 145,010 shares of the company’s stock, valued at $2,507,222.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $18.37, for a total transaction of $30,604.42. Following the completion of the sale, the director now owns 121,375 shares in the company, valued at $2,229,658.75. The disclosure for this sale can be found here. Insiders sold 110,955 shares of company stock valued at $2,218,802 over the last three months. Company insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DNLI. Principal Financial Group Inc. raised its stake in shares of Denali Therapeutics by 4.5% during the 1st quarter. Principal Financial Group Inc. now owns 1,122,536 shares of the company’s stock worth $23,034,000 after purchasing an additional 48,832 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Denali Therapeutics by 67.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 26,721 shares of the company’s stock worth $548,000 after acquiring an additional 10,740 shares in the last quarter. Wasatch Advisors LP lifted its stake in Denali Therapeutics by 28.9% in the first quarter. Wasatch Advisors LP now owns 402,670 shares of the company’s stock valued at $8,263,000 after acquiring an additional 90,369 shares during the last quarter. Los Angeles Capital Management LLC grew its position in shares of Denali Therapeutics by 19.4% in the 1st quarter. Los Angeles Capital Management LLC now owns 55,612 shares of the company’s stock valued at $1,141,000 after acquiring an additional 9,054 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in shares of Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after purchasing an additional 807 shares during the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.